抗CTLA-4 [9H10]組換え抗体 | Anti-CTLA-4 [9H10] recombinant antibody
掲載日情報:2019/10/24 現在Webページ番号:219192
Absolute Antibody社の抗CTLA-4 [9H10]組換え抗体(リコンビナント抗体)( Anti-CTLA-4 [9H10] recombinant antibody)です。
※本製品は研究用です。研究用以外には使用できません。
追加しました。
価格
[在庫・価格 :2025年05月10日 00時01分現在]
詳細 | 商品名 |
|
文献数 | ||
---|---|---|---|---|---|
Anti-CTLA-4, Hamster (Armenian)-Mono [9H10], IgG, Purified Recombinant Antibody |
|
0 | |||
Anti-CTLA-4, Hamster (Armenian)-Mono [9H10], IgG, Purified Recombinant Antibody |
|
0 | |||
[在庫・価格 :2025年05月10日 00時01分現在]
Anti-CTLA-4, Hamster (Armenian)-Mono [9H10], IgG, Purified Recombinant Antibody
文献数: 0
- 商品コード:Ab00894-22.0
- メーカー:ABA
- 包装:200μg
- 価格:¥141,000
- 在庫:無(未発注)
- 納期:2~3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 | 別名:CD152,CTLA4,cytotoxic T-lymphocyte-associated antigen 4,Cytotoxic T-lymphocyte protein 4 クローン:9H10 |
||
---|---|---|---|
法規制等 | |||
保存条件 | 法規備考 | ||
抗原種 | 免疫動物 | ||
交差性 | Mouse | 適用 | ELISA,FCM,Western Blot |
標識 | Unlabeled | 性状 | |
吸収処理 | クラス | IgG | |
クロナリティ | Recombinant | フォーマット | |
掲載カタログ |
|
||
製品記事 | |||
関連記事 |
Anti-CTLA-4, Hamster (Armenian)-Mono [9H10], IgG, Purified Recombinant Antibody
文献数: 0
- 商品コード:Ab00894-22.0-BT
- メーカー:ABA
- 包装:1mg
- 価格:ご照会ください
- 在庫:無(未発注)
- 納期:2~3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 | 別名:CD152,CTLA4,cytotoxic T-lymphocyte-associated antigen 4,Cytotoxic T-lymphocyte protein 4 クローン:9H10 |
||
---|---|---|---|
法規制等 | |||
保存条件 | 法規備考 | ||
抗原種 | 免疫動物 | ||
交差性 | Mouse | 適用 | ELISA,FCM,Western Blot |
標識 | Unlabeled | 性状 | |
吸収処理 | クラス | IgG | |
クロナリティ | Recombinant | フォーマット | |
掲載カタログ |
|
||
製品記事 | |||
関連記事 |
追加しました。
製品情報
Description | Recombinant monoclonal antibody to CTLA-4. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 9H10. |
---|---|
Species and Isotype | Hamster (Armenian) IgG, kappa |
Clone Number | 9H10 |
UniProt Accession Number of Target Protein | P09793 |
Published Application(s) | Neutralisation; WB; FC; ELISA; proliferation assays |
Published Species Reactivity | Mouse |
Immunogen | This antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas. |
Specificity | This antibody is specific for murine CTLA-4, an inhibitory receptor that acts as the primary negative regulator of T-cell responses. CTLA-4 is expressed predominantly by activated T cells, with significantly higher levels of expression on CD8+ T cells than CD4+ T cells. |
Application Notes | CTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses; CTLA-4 binds to the B7 molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999). |
Antibody First Published in | Krummel & Allison CD28 and CTLA-4 Have Opposing Effects on the Response of T cells to Stimulation J Exp Med. 1995 Aug 1; 182(2): 459–465. PMID:7543139 |
Note on publication | Describes the original generation and characterisation of this antibody. |
Purification | Protein A affinity purified |
Supplied in | Bulk size: PBS only. Standard size: PBS with 0.02% Proclin 300. |
Storage Recommendation | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C |
Concentration | See vial label. |
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。